{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:41:14Z","timestamp":1792788074267,"version":"4.5.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2023A1515011495"],"award-info":[{"award-number":["2023A1515011495"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Guangdong Medical Products Administration Scientific and Technological Innovation Project","award":["2021ZDB01"],"award-info":[{"award-number":["2021ZDB01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This systematic review of randomized controlled trials (RCT) was conducted to evaluate the efficacy of enzyme replacement therapy (ERT) for patients with mucopolysaccharidosis (MPS). We systematically searched PubMed, Embase, Web of Science, and Cochrane databases up to August 22, 2023. Study design, interventions, and outcome data were extracted. Continuous variable random-effects network meta-analysis was performed. The review included 23 studies involving 1,047 people with MPS I\u2013VI. In MPS I, urinary glycosaminoglycan (uGAG) level was significantly reduced in patients who took 2\u00a0mg\/kg\/week pentosan polysulfate (-2.66, 95% confidence interval (CI)[-3.86, -1.46]) compared with those who took 1\u00a0mg\/kg\/week. In MPS II, compared with the placebo group, significant reduction were observed in the uGAG (-270.77, 95% CI[-406.57, -139.71]) and the cerebrospinal fluid (CSF) GAG (-1,385.29, 95% CI[-2493.33, -392.65]). In MPS IV, 6-min walking test (6MWT) (40.82, 95% CI[16.19, 64.92]) and 3-min stair climb test (3MSCT) (16.07, 95% CI[12.16, 21.62]) were significantly increased in patients who took elosulfase alfa at a dose of 4.0\u00a0mg\/kg\/week compared with the placebo group. In MPS VI, recombinant human arylsulfatase B (rhASB) and galsulfase (1.0\u00a0mg\/kg\/week) significantly reduced uGAG aggregation compared with the placebo group (-217, 95% CI[-258, -176]) and galsulfase (2.0\u00a0mg\/kg\/week) group (-286.5, 95% CI[-436.5, -136.5]), respectively. Moreover, most studies had high (34.8%) or unclear (43.5%) risk of bias assessments and confidence assessment were low. ERT alleviated symptoms to some extent, but current evidence was insufficient. Hence, further evidence from large-sample RCT is needed.<\/jats:p>","DOI":"10.1186\/s13023-025-03735-y","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T09:50:51Z","timestamp":1746179451000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of different treatment strategies in patients with mucopolysaccharidosis: a systematic review and network meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"20","author":[{"given":"Lingling","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianru","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biyu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenfang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong Qiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"issue":"1","key":"3735_CR1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s13023-021-01880-8","volume":"16","author":"Y Puckett","year":"2021","unstructured":"Puckett Y, Mallorga-Hern\u00e1ndez A, Monta\u00f1o AM. Epidemiology of mucopolysaccharidoses (MPS) in united States: challenges and opportunities. Orphanet J Rare Dis. 2021;16(1):241.","journal-title":"Orphanet J Rare Dis"},{"issue":"Suppl 2","key":"3735_CR2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13052-018-0550-5","volume":"44","author":"C Galimberti","year":"2018","unstructured":"Galimberti C, Madeo A, Di Rocco M, Fiumara A. Mucopolysaccharidoses: early diagnostic signs in infants and children. Ital J Pediatr. 2018;44(Suppl 2):133.","journal-title":"Ital J Pediatr"},{"issue":"3","key":"3735_CR3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ymgme.2017.05.016","volume":"121","author":"SA Khan","year":"2017","unstructured":"Khan SA, Peracha H, Ballhausen D, Wiesbauer A, Rohrbach M, Gautschi M, et al. Epidemiology of mucopolysaccharidoses. Mol Genet Metab. 2017;121(3):227\u201340.","journal-title":"Mol Genet Metab"},{"key":"3735_CR4","doi-asserted-by":"crossref","unstructured":"De Ponti G, Donsante S, Frigeni M, Pievani A, Corsi A, Bernardo ME et al. MPSI manifestations and treatment outcome: skeletal focus. Int J Mol Sci. 2022;23(19).","DOI":"10.3390\/ijms231911168"},{"issue":"1","key":"3735_CR5","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13023-017-0583-7","volume":"12","author":"BT Kiely","year":"2017","unstructured":"Kiely BT, Kohler JL, Coletti HY, Poe MD, Escolar ML. Early disease progression of hurler syndrome. Orphanet J Rare Dis. 2017;12(1):32.","journal-title":"Orphanet J Rare Dis"},{"key":"3735_CR6","doi-asserted-by":"crossref","unstructured":"Hampe CS, Wesley J, Lund TC, Orchard PJ, Polgreen LE, Eisengart JB et al. Mucopolysaccharidosis type I: current treatments, limitations, and prospects for improvement. Biomolecules. 2021;11(2).","DOI":"10.3390\/biom11020189"},{"key":"3735_CR7","doi-asserted-by":"crossref","unstructured":"Hampe CS, Eisengart JB, Lund TC, Orchard PJ, Swietlicka M, Wesley J et al. Mucopolysaccharidosis type I: A review of the natural history and molecular pathology. Cells. 2020;9(8).","DOI":"10.3390\/cells9081838"},{"issue":"4","key":"3735_CR8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1590\/S1415-47572010005000093","volume":"33","author":"R Giugliani","year":"2010","unstructured":"Giugliani R, Federhen A, Rojas MV, Vieira T, Artigal\u00e1s O, Pinto LL, et al. Mucopolysaccharidosis I, II, and VI: brief review and guidelines for treatment. Genet Mol Biol. 2010;33(4):589\u2013604.","journal-title":"Genet Mol Biol"},{"issue":"2","key":"3735_CR9","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ymgme.2017.04.004","volume":"121","author":"J P\u00e9rez-L\u00f3pez","year":"2017","unstructured":"P\u00e9rez-L\u00f3pez J, Morales-Conejo M, L\u00f3pez-Rodr\u00edguez M, Hermida-Ameijeiras \u00c1, Molt\u00f3-Abad M. Efficacy of laronidase therapy in patients with mucopolysaccharidosis type I who initiated enzyme replacement therapy in adult age. A systematic review and meta-analysis. Mol Genet Metab. 2017;121(2):138\u201349.","journal-title":"Mol Genet Metab"},{"key":"3735_CR10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1750-1172-3-24","volume":"3","author":"D Moore","year":"2008","unstructured":"Moore D, Connock MJ, Wraith E, Lavery C. The prevalence of and survival in mucopolysaccharidosis I: hurler, Hurler-Scheie and scheie syndromes in the UK. Orphanet J Rare Dis. 2008;3:24.","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"3735_CR11","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/gim.2018.29","volume":"20","author":"JB Eisengart","year":"2018","unstructured":"Eisengart JB, Rudser KD, Xue Y, Orchard P, Miller W, Lund T, et al. Long-term outcomes of systemic therapies for hurler syndrome: an international multicenter comparison. Genet Med. 2018;20(11):1423\u20139.","journal-title":"Genet Med"},{"issue":"3","key":"3735_CR12","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","volume":"167","author":"JE Wraith","year":"2008","unstructured":"Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, Guffon N, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008;167(3):267\u201377.","journal-title":"Eur J Pediatr"},{"issue":"1","key":"3735_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ymgme.2007.01.011","volume":"91","author":"GM Pastores","year":"2007","unstructured":"Pastores GM, Arn P, Beck M, Clarke JTR, Guffon N, Kaplan P, et al. The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with mucopolysaccharidosis type I. Mol Genet Metab. 2007;91(1):37\u201347.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"3735_CR14","first-page":"65","volume":"2012","author":"S Tomatsu","year":"2012","unstructured":"Tomatsu S, Mackenzie WG, Theroux MC, Mason RW, Thacker MM, Shaffer TH, et al. Current and emerging treatments and surgical interventions for Morquio A syndrome: a review. Res Rep Endocr Disord. 2012;2012(2):65\u201377.","journal-title":"Res Rep Endocr Disord"},{"issue":"6","key":"3735_CR15","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2174\/138920111795542615","volume":"12","author":"S Tomatsu","year":"2011","unstructured":"Tomatsu S, Monta\u00f1o AM, Oikawa H, Smith M, Barrera L, Chinen Y, et al. Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment. Curr Pharm Biotechnol. 2011;12(6):931\u201345.","journal-title":"Curr Pharm Biotechnol"},{"issue":"1","key":"3735_CR16","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.1016\/j.ymgme.2016.11.285","volume":"120","author":"Y Puckett","year":"2017","unstructured":"Puckett Y, Bui E, Zelicoff A, Montano A. Epidemiology of mucopolysaccharidoses (MPS) in the united States: challenges and opportunities. Mol Genet Metab. 2017;120(1):S111.","journal-title":"Mol Genet Metab"},{"key":"3735_CR17","first-page":"21","volume":"25","author":"E Kiykim","year":"2016","unstructured":"Kiykim E, Barut K, Cansever MS, Zeybek CA, Zubarioglu T, Aydin A, et al. Screening mucopolysaccharidosis type IX in patients with juvenile idiopathic arthritis. JIMD Rep. 2016;25:21\u20134.","journal-title":"JIMD Rep"},{"issue":"1","key":"3735_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ymgme.2021.03.002","volume":"133","author":"EG Shapiro","year":"2021","unstructured":"Shapiro EG, Eisengart JB. The natural history of neurocognition in MPS disorders: A review. Mol Genet Metab. 2021;133(1):8\u201334.","journal-title":"Mol Genet Metab"},{"key":"3735_CR19","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.pedneo.2022.10.001","volume":"64","author":"M Penon-Portmann","year":"2023","unstructured":"Penon-Portmann M, Blair DR, Harmatz P. Current and new therapies for mucopolysaccharidoses. Pediatr Neonatology. 2023;64:S10\u20137.","journal-title":"Pediatr Neonatology"},{"issue":"2","key":"3735_CR20","doi-asserted-by":"publisher","first-page":"132","DOI":"10.2174\/156652311794940791","volume":"11","author":"DS Anson","year":"2011","unstructured":"Anson DS, McIntyre C, Byers S. Therapies for neurological disease in the mucopolysaccharidoses. Curr Gene Ther. 2011;11(2):132\u201343.","journal-title":"Curr Gene Ther"},{"issue":"11","key":"3735_CR21","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/s10038-019-0662-9","volume":"64","author":"HH Chen","year":"2019","unstructured":"Chen HH, Sawamoto K, Mason RW, Kobayashi H, Yamaguchi S, Suzuki Y, et al. Enzyme replacement therapy for mucopolysaccharidoses; past, present, and future. J Hum Genet. 2019;64(11):1153\u201371.","journal-title":"J Hum Genet"},{"key":"3735_CR22","doi-asserted-by":"crossref","unstructured":"Rossi A, Brunetti-Pierri N. Gene therapies for mucopolysaccharidoses. J Inherit Metab Dis. 2023.","DOI":"10.1002\/jimd.12626"},{"issue":"5","key":"3735_CR23","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1002\/jimd.12615","volume":"46","author":"S Ellison","year":"2023","unstructured":"Ellison S, Parker H, Bigger B. Advances in therapies for neurological lysosomal storage disorders. J Inherit Metab Dis. 2023;46(5):874\u2013905.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"3735_CR24","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1080\/00273171.2022.2115965","volume":"58","author":"Y Liu","year":"2023","unstructured":"Liu Y, B\u00e9liveau A, Wei Y, Chen MY, Record-Lemon R, Kuo PL, et al. A gentle introduction to bayesian network Meta-Analysis using an automated R package. Multivar Behav Res. 2023;58(4):706\u201322.","journal-title":"Multivar Behav Res"},{"issue":"4","key":"3735_CR25","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","volume":"7","author":"SP Brooks","year":"1998","unstructured":"Brooks SP, Gelman A. General methods for monitoring convergence of iterative simulations. J Comput Graphical Stat. 1998;7(4):434\u201355.","journal-title":"J Comput Graphical Stat"},{"issue":"2","key":"3735_CR26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.35566\/jbds\/v2n2\/p3","volume":"2","author":"H Du","year":"2022","unstructured":"Du H, Ke Z, Jiang G, Huang S. The performances of Gelman-Rubin and Geweke\u2019s convergence diagnostics of Monte Carlo Markov chains in bayesian analysis. J Behav Data Sci. 2022;2(2):47\u201372.","journal-title":"J Behav Data Sci"},{"issue":"7","key":"3735_CR27","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1177\/1474515120944014","volume":"19","author":"T Ruppar","year":"2020","unstructured":"Ruppar T. Meta-analysis: how to quantify and explain heterogeneity? Eur J Cardiovasc Nurs. 2020;19(7):646\u201352.","journal-title":"Eur J Cardiovasc Nurs"},{"issue":"1","key":"3735_CR28","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1515\/ijb-2022-0070","volume":"20","author":"D Stogiannis","year":"2024","unstructured":"Stogiannis D, Siannis F, Androulakis E. Heterogeneity in meta-analysis: a comprehensive overview. Int J Biostatistics. 2024;20(1):169\u201399.","journal-title":"Int J Biostatistics"},{"issue":"1","key":"3735_CR29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1167","volume":"7","author":"G van Valkenhoef","year":"2016","unstructured":"van Valkenhoef G, Dias S, Ades AE, Welton NJ. Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis. Res Synth Methods. 2016;7(1):80\u201393.","journal-title":"Res Synth Methods"},{"issue":"7\u20138","key":"3735_CR30","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/sim.3767","volume":"29","author":"S Dias","year":"2010","unstructured":"Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010;29(7\u20138):932\u201344.","journal-title":"Stat Med"},{"issue":"2","key":"3735_CR31","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti G, Ades AE, Ioannidis JPA. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163\u201371.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"3735_CR32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","volume":"12","author":"B Rouse","year":"2017","unstructured":"Rouse B, Chaimani A, Li T. Network meta-analysis: an introduction for clinicians. Intern Emerg Med. 2017;12(1):103\u201311.","journal-title":"Intern Emerg Med"},{"issue":"7","key":"3735_CR33","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1016\/j.ymthe.2021.03.019","volume":"29","author":"R Giugliani","year":"2021","unstructured":"Giugliani R, Martins AM, So S, Yamamoto T, Yamaoka M, Ikeda T, et al. Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp Alfa, for MPS-II: A phase 2 trial in Brazil. Mol Ther. 2021;29(7):2378\u201386.","journal-title":"Mol Ther"},{"issue":"2","key":"3735_CR34","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10545-013-9654-7","volume":"37","author":"PR Harmatz","year":"2014","unstructured":"Harmatz PR, Garcia P, Guffon N, Randolph LM, Shediac R, Braunlin E, et al. Galsulfase (Naglazyme\u00ae) therapy in infants with mucopolysaccharidosis VI. J Inherit Metab Dis. 2014;37(2):277\u201387.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"3735_CR35","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/jimd.12467","volume":"45","author":"N Guffon","year":"2022","unstructured":"Guffon N, Chowdary P, Teles EL, Hughes D, Hennermann JB, Huot-Marchand P, et al. Oral treatment for mucopolysaccharidosis VI: outcomes of the first phase IIa study with odiparcil. J Inherit Metab Dis. 2022;45(2):340\u201352.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"3735_CR36","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jpeds.2005.12.014","volume":"148","author":"P Harmatz","year":"2006","unstructured":"Harmatz P, Giugliani R, Schwartz I, Guffon N, Teles EL, Miranda MCS, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of Recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr. 2006;148(4):533\u2013e.","journal-title":"J Pediatr"},{"key":"3735_CR37","doi-asserted-by":"crossref","unstructured":"Lee CL, Chuang CK, Syu YM, Chiu HC, Tu YR, Lo YT et al. Efficacy of intravenous elosulfase Alfa for mucopolysaccharidosis type IVA: A systematic review and Meta-Analysis. J Pers Med. 2022;12(8).","DOI":"10.3390\/jpm12081338"},{"issue":"1","key":"3735_CR38","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ymgme.2020.07.005","volume":"131","author":"PE Wikman-Jorgensen","year":"2020","unstructured":"Wikman-Jorgensen PE, L\u00f3pez Amor\u00f3s A, Peris Garc\u00eda J, Esteve Atienzar PJ, Ca\u00f1izares Navarro R, Asensio Tom\u00e1s ML, et al. Enzyme replacement therapy for the treatment of Hunter disease: A systematic review with narrative synthesis and meta-analysis. Mol Genet Metab. 2020;131(1):206\u201310.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"3735_CR39","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ymgme.2021.03.006","volume":"133","author":"P Garcia","year":"2021","unstructured":"Garcia P, Phillips D, Johnson J, Martin K, Randolph LM, Rosenfeld H, et al. Long-term outcomes of patients with mucopolysaccharidosis VI treated with galsulfase enzyme replacement therapy since infancy. Mol Genet Metab. 2021;133(1):100\u20138.","journal-title":"Mol Genet Metab"},{"key":"3735_CR40","first-page":"63","volume":"7","author":"HY Lin","year":"2016","unstructured":"Lin HY, Chuang CK, Wang CH, Chien YH, Wang YM, Tsai FJ, et al. Long-term galsulfase enzyme replacement therapy in Taiwanese mucopolysaccharidosis VI patients: A case series. Mol Genet Metab Rep. 2016;7:63\u20139.","journal-title":"Mol Genet Metab Rep"},{"issue":"3","key":"3735_CR41","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ymgme.2020.01.003","volume":"129","author":"RY Wang","year":"2020","unstructured":"Wang RY, da Silva Franco JF, L\u00f3pez-Valdez J, Martins E, Sutton VR, Whitley CB, et al. The long-term safety and efficacy of vestronidase Alfa, RhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII. Mol Genet Metab. 2020;129(3):219\u201327.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"3735_CR42","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.pedneo.2018.08.005","volume":"60","author":"HY Lin","year":"2019","unstructured":"Lin HY, Chuang CK, Ke YY, Hsu CC, Chiu PC, Niu DM, et al. Long-term effects of enzyme replacement therapy for Taiwanese patients with mucopolysaccharidosis IVA. Pediatr Neonatol. 2019;60(3):342\u20133.","journal-title":"Pediatr Neonatol"},{"issue":"1","key":"3735_CR43","first-page":"251","volume":"69","author":"J Marucha","year":"2022","unstructured":"Marucha J, Lipi\u0144ski P, Tylki-Szyma\u0144ska A. Efficacy of enzyme replacement therapy on the range of motion of the upper and lower extremities in 16 Polish patients with mucopolysaccharidosis type II: A long-term follow-up study. Acta Biochim Pol. 2022;69(1):251\u20135.","journal-title":"Acta Biochim Pol"},{"issue":"5","key":"3735_CR44","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.pedneo.2019.05.005","volume":"60","author":"HY Lin","year":"2019","unstructured":"Lin HY, Lee CL, Chuang CK, Lin SP. Long-term outcomes of enzyme replacement therapy for Taiwanese patients with mucopolysaccharidosis I. Pediatr Neonatol. 2019;60(5):577\u20138.","journal-title":"Pediatr Neonatol"},{"issue":"Suppl 2","key":"3735_CR45","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13052-018-0562-1","volume":"44","author":"D Concolino","year":"2018","unstructured":"Concolino D, Deodato F, Parini R. Enzyme replacement therapy: efficacy and limitations. Ital J Pediatr. 2018;44(Suppl 2):120.","journal-title":"Ital J Pediatr"},{"key":"3735_CR46","first-page":"100816","volume":"29","author":"K Tomita","year":"2021","unstructured":"Tomita K, Okamoto S, Seto T, Hamazaki T. Real world long-term outcomes in patients with mucopolysaccharidosis type II: A retrospective cohort study. Mol Genet Metab Rep. 2021;29:100816.","journal-title":"Mol Genet Metab Rep"},{"issue":"1\u20132","key":"3735_CR47","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ymgme.2022.08.007","volume":"137","author":"JJ Mitchell","year":"2022","unstructured":"Mitchell JJ, Burton BK, Bober MB, Campeau PM, Cohen S, Dosenovic S, et al. Findings from the Morquio A registry study (MARS) after 6 years: Long-term outcomes of MPS IVA patients treated with elosulfase Alfa. Mol Genet Metab. 2022;137(1\u20132):164\u201372.","journal-title":"Mol Genet Metab"},{"key":"3735_CR48","first-page":"143","volume":"16","author":"CL Lee","year":"2022","unstructured":"Lee CL, Chuang CK, Chiu HC, Tu RY, Lo YT, Chang YH, et al. Clinical utility of elosulfase Alfa in the treatment of Morquio A syndrome. Drug Des Devel Ther. 2022;16:143\u201354.","journal-title":"Drug Des Devel Ther"},{"issue":"21","key":"3735_CR49","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa2106596","volume":"385","author":"B Gentner","year":"2021","unstructured":"Gentner B, Tucci F, Galimberti S, Fumagalli F, De Pellegrin M, Silvani P, et al. Hematopoietic Stem- and Progenitor-Cell gene therapy for hurler syndrome. N Engl J Med. 2021;385(21):1929\u201340.","journal-title":"N Engl J Med"},{"key":"3735_CR50","doi-asserted-by":"crossref","unstructured":"Zapolnik P, Pyrkosz A. Gene therapy for mucopolysaccharidosis type II-A review of the current possibilities. Int J Mol Sci. 2021;22(11).","DOI":"10.3390\/ijms22115490"},{"issue":"2","key":"3735_CR51","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ymgme.2017.12.434","volume":"123","author":"K Sawamoto","year":"2018","unstructured":"Sawamoto K, Chen HH, Alm\u00e9ciga-D\u00edaz CJ, Mason RW, Tomatsu S. Gene therapy for mucopolysaccharidoses. Mol Genet Metab. 2018;123(2):59\u201368.","journal-title":"Mol Genet Metab"},{"key":"3735_CR52","doi-asserted-by":"publisher","first-page":"965089","DOI":"10.3389\/fmolb.2022.965089","volume":"9","author":"SR Wood","year":"2022","unstructured":"Wood SR, Bigger BW. Delivering gene therapy for mucopolysaccharide diseases. Front Mol Biosci. 2022;9:965089.","journal-title":"Front Mol Biosci"},{"issue":"1","key":"3735_CR53","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/jimd.12316","volume":"44","author":"B Seker Yilmaz","year":"2021","unstructured":"Seker Yilmaz B, Davison J, Jones SA, Baruteau J. Novel therapies for mucopolysaccharidosis type III. J Inherit Metab Dis. 2021;44(1):129\u201347.","journal-title":"J Inherit Metab Dis"},{"issue":"7","key":"3735_CR54","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1021\/acsmedchemlett.0c00042","volume":"11","author":"S Olarte-Avellaneda","year":"2020","unstructured":"Olarte-Avellaneda S, Del Cepeda J, Rojas-Rodriguez AF, S\u00e1nchez O, Rodr\u00edguez-L\u00f3pez A, Su\u00e1rez Garc\u00eda DA, et al. Bromocriptine as a novel Pharmacological chaperone for mucopolysaccharidosis IV A. ACS Med Chem Lett. 2020;11(7):1377\u201385.","journal-title":"ACS Med Chem Lett"},{"key":"3735_CR55","doi-asserted-by":"crossref","unstructured":"Coutinho MF, Santos JI, Alves S. Less is more: substrate reduction therapy for lysosomal storage disorders. Int J Mol Sci. 2016;17(7).","DOI":"10.3390\/ijms17071065"},{"key":"3735_CR56","doi-asserted-by":"crossref","unstructured":"Coutinho MF, Santos JI, Matos L, Alves S. Genetic substrate reduction therapy: A promising approach for lysosomal storage disorders. Diseases. 2016;4(4).","DOI":"10.3390\/diseases4040033"},{"key":"3735_CR57","doi-asserted-by":"crossref","unstructured":"Losada D\u00edaz JC, Del Cepeda J, Rodriguez-L\u00f3pez EA, Alm\u00e9ciga-D\u00edaz CJ. Advances in the development of Pharmacological chaperones for the mucopolysaccharidoses. Int J Mol Sci. 2019;21(1).","DOI":"10.3390\/ijms21010232"},{"key":"3735_CR58","doi-asserted-by":"crossref","unstructured":"Sawamoto K, \u00c1lvarez Gonz\u00e1lez JV, Piechnik M, Otero FJ, Couce ML, Suzuki Y et al. Mucopolysaccharidosis IVA: diagnosis, treatment, and management. Int J Mol Sci. 2020;21(4).","DOI":"10.3390\/ijms21041517"},{"issue":"1","key":"3735_CR59","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13023-021-01743-2","volume":"16","author":"HY Lin","year":"2021","unstructured":"Lin HY, Chen MR, Lee CL, Lin SM, Hung CL, Niu DM, et al. Natural progression of cardiac features and long-term effects of enzyme replacement therapy in Taiwanese patients with mucopolysaccharidosis II. Orphanet J Rare Dis. 2021;16(1):99.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"3735_CR60","doi-asserted-by":"publisher","first-page":"e0162612","DOI":"10.1371\/journal.pone.0162612","volume":"11","author":"C Kampmann","year":"2016","unstructured":"Kampmann C, Abu-Tair T, G\u00f6kce S, Lampe C, Reinke J, Mengel E, et al. Heart and cardiovascular involvement in patients with mucopolysaccharidosis type IVA (Morquio-A Syndrome). PLoS ONE. 2016;11(9):e0162612.","journal-title":"PLoS ONE"},{"issue":"4","key":"3735_CR61","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ymgme.2016.02.003","volume":"117","author":"HY Lin","year":"2016","unstructured":"Lin HY, Chuang CK, Chen MR, Lin SM, Hung CL, Chang CY, et al. Cardiac structure and function and effects of enzyme replacement therapy in patients with mucopolysaccharidoses I, II, IVA and VI. Mol Genet Metab. 2016;117(4):431\u20137.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"3735_CR62","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00246-019-02267-0","volume":"41","author":"DA do Valle","year":"2020","unstructured":"do Valle DA, Cirino RHD, Santos M, Pellissari EC, Scola RH. Enzyme replacement therapy decreases left ventricular mass index in patients with Hunter syndrome?? Pediatr Cardiol. 2020;41(2):361\u20135.","journal-title":"Pediatr Cardiol"},{"issue":"1\u20132","key":"3735_CR63","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ymgme.2015.06.002","volume":"116","author":"EG Shapiro","year":"2015","unstructured":"Shapiro EG, Nestrasil I, Rudser K, Delaney K, Kovac V, Ahmed A, et al. Neurocognition across the spectrum of mucopolysaccharidosis type I: age, severity, and treatment. Mol Genet Metab. 2015;116(1\u20132):61\u20138.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"3735_CR64","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.jpeds.2008.11.005","volume":"154","author":"RF Wynn","year":"2009","unstructured":"Wynn RF, Wraith JE, Mercer J, O\u2019Meara A, Tylee K, Thornley M, et al. Improved metabolic correction in patients with lysosomal storage disease treated with hematopoietic stem cell transplant compared with enzyme replacement therapy. J Pediatr. 2009;154(4):609\u201311.","journal-title":"J Pediatr"},{"issue":"1","key":"3735_CR65","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13023-017-0634-0","volume":"12","author":"D Hughes","year":"2017","unstructured":"Hughes D, Giugliani R, Guffon N, Jones SA, Mengel KE, Parini R, et al. Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase Alfa. Orphanet J Rare Dis. 2017;12(1):98.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3735_CR66","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ymgme.2016.05.018","volume":"119","author":"CJ Hendriksz","year":"2016","unstructured":"Hendriksz CJ, Parini R, AlSayed MD, Raiman J, Giugliani R, Solano Villarreal ML, et al. Long-term endurance and safety of elosulfase Alfa enzyme replacement therapy in patients with Morquio A syndrome. Mol Genet Metab. 2016;119(1):131\u201343.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"3735_CR67","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ymgme.2017.11.015","volume":"123","author":"CJ Hendriksz","year":"2018","unstructured":"Hendriksz CJ, Parini R, AlSayed MD, Raiman J, Giugliani R, Mitchell JJ, et al. Impact of long-term elosulfase Alfa on activities of daily living in patients with Morquio A syndrome in an open-label, multi-center, phase 3 extension study. Mol Genet Metab. 2018;123(2):127\u201334.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"3735_CR68","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ymgme.2022.08.007","volume":"137","author":"JJ Mitchell","year":"2022","unstructured":"Mitchell JJ, Burton BK, Bober MB, Campeau PM, Cohen S, Dosenovic S, et al. Findings from the Morquio A registry study (MARS) after 6 years: Long-term outcomes of MPS IVA patients treated with elosulfase Alfa. Mol Genet Metab. 2022;137(1):164\u201372.","journal-title":"Mol Genet Metab"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03735-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03735-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03735-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T11:03:29Z","timestamp":1746183809000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03735-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3735"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03735-y","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,2]]},"assertion":[{"value":"15 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The funder\/sponsor did not participate in the work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Role of Funder\/Sponsor"}},{"value":"The authors have no conflicts of interest to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"211"}}